Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy

The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of an...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamaï, Ahmed, Duperrier-Amouriaux, Karine, Pignon, Pascale, Raimbaud, Isabelle, Memeo, Lorenzo, Colarossi, Cristina, Canzonieri, Vincenzo, Perin, Tiziana, Classe, Jean-Marc, Campone, Mario, Jézéquel, Pascal, Campion, Loïc, Ayyoub, Maha, Valmori, Danila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117860/
https://www.ncbi.nlm.nih.gov/pubmed/21747904
http://dx.doi.org/10.1371/journal.pone.0021129

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3117860/
https://www.ncbi.nlm.nih.gov/pubmed/21747904
http://dx.doi.org/10.1371/journal.pone.0021129

Ejemplares similares